Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06814717 · ClinicalTrials.gov registry record · Phase 2
A Safety, Tolerability and Pharmacokinetic Study of cP12 in Adults With Up To 10% Total Body Surface Area Burns
A Phase 2 study of Thermal Burns, sponsored by Neomatrix Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT06814717: Recruiting Phase 2 study of Thermal Burns, sponsored by Neomatrix Therapeutics.
NCT06814717 is a Phase 2 study of Thermal Burns that is actively recruiting participants, run by Neomatrix Therapeutics. The registered enrollment target is 6 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06814717, a Phase 2 study of Thermal Burns, is actively recruiting participants, sponsored by Neomatrix Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 2a, open-label, single-dose study to evaluate the safety, tolerability, and PK profile of cP12 in 6 male and female subjects with thermal burns of up to and including 10% TBSA. Enrolled subjects must have at least 1% superficial (epidermal), superficial partial-thickness, or deep partial-thickness burns. Eligible subjects will receive a single administration of 0.01 mg/kg cP12. Vital signs, ECGs, and blood samples and urine samples will be obtained at screening and at several time points during the study for safety evaluation. Burn and pain assessments will be completed at specified times. Subjects will remain at the clinical site for at least 6 hours post infusion for the purpose of safety monitoring and evaluation of other study assessments. Subsequent evaluations will be performed at the clinical site 3 (±1) days and 7 (±2) days after dosing. Subjects will return to the clinical site 14 (±2) days after dosing for an End-of-Study visit.
Conditions Studied
Interventions
- DRUG cP12
Study Locations (1)
District of Columbia
- Medstar Washington Hospital Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2025-05-12 |
| Est. Completion | 2026-11-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06814717
The ClinicalTrials.gov registry entry for NCT06814717 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neomatrix Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Thermal Burns appearing as the primary indexed condition, and to 1 intervention - of which cP12 is the first listed.
NCT06814717 reports 1 study location spanning 1 distinct geographic area - top geographies include District of Columbia.
Frequently Asked Questions
What is clinical trial NCT06814717 about?
NCT06814717 is a clinical study titled "A Safety, Tolerability and Pharmacokinetic Study of cP12 in Adults With Up To 10% Total Body Surface Area Burns". This is a Phase 2a, open-label, single-dose study to evaluate the safety, tolerability, and PK profile of cP12 in 6 male and female subjects with thermal burns of up to and including 10% TBSA. Enrolled subjects must have at least 1% superficial (epidermal), superficial partial-thickness, or deep par...
What is the current status of trial NCT06814717?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2025-05-12. Estimated completion is 2026-11-01.
What conditions does trial NCT06814717 study?
This clinical trial studies the following conditions: Thermal Burns.
What interventions are being tested in trial NCT06814717?
The interventions under investigation include: cP12 (DRUG).
Who is sponsoring clinical trial NCT06814717?
This trial is sponsored by Neomatrix Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06814717 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thermal Burns
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.